Phase I Study of Dystrophin Plasmid-Based Gene Therapy in Duchenne/Becker Muscular Dystrophy

2004 ◽  
Vol 15 (11) ◽  
pp. 1065-1076 ◽  
Author(s):  
Norma B. Romero ◽  
Serge Braun ◽  
Olivier Benveniste ◽  
France Leturcq ◽  
Jean-Yves Hogrel ◽  
...  
2013 ◽  
pp. 150127063140004
Author(s):  
Wei-Li Di ◽  
Jemima E Mellerio ◽  
Catina Bernadis ◽  
John Harper ◽  
Alya Abdul-Wahab ◽  
...  

2017 ◽  
Vol 56 (7) ◽  
pp. 909-916 ◽  
Author(s):  
Iben Spanggaard ◽  
Karin Dahlstroem ◽  
Line Laessoee ◽  
Rasmus Hvass Hansen ◽  
Helle Hjorth Johannesen ◽  
...  

2001 ◽  
pp. 1291-1295 ◽  
Author(s):  
LEONARD G. GOMELLA ◽  
MICHAEL J. MASTRANGELO ◽  
PETER A. McCUE ◽  
HENRY C. MAGUIRE ◽  
S. GRANT MULHOLLAND ◽  
...  

Neurology ◽  
1998 ◽  
Vol 51 (2) ◽  
pp. 592-595 ◽  
Author(s):  
M. Mirabella ◽  
G. Galluzzi ◽  
G. Manfredi ◽  
E. Bertini ◽  
E. Ricci ◽  
...  

We report a patient with a large intragenic dystrophin deletion of exons 17-51 inclusive associated with congenital cataract and mild Becker muscular dystrophy. The cataract was similar to the congenital cataract described in the mdx mouse. The loss of 68% of the rod domain including hinge 2 and 3 regions did not adversely affect the correct localization of the dystrophin and the association with the dystrophin-associated glycoprotein complex. This observation may have implications for minigenes suitable for gene therapy.


2013 ◽  
Vol 21 (5) ◽  
pp. 922-923 ◽  
Author(s):  
Christopher Larson ◽  
Natalie Mendez ◽  
Tony Reid
Keyword(s):  
Phase I ◽  

1991 ◽  
Vol 28 (12) ◽  
pp. 860-864 ◽  
Author(s):  
D R Love ◽  
T J Flint ◽  
S A Genet ◽  
H R Middleton-Price ◽  
K E Davies

2005 ◽  
Vol 11 (4) ◽  
pp. 1512-1520 ◽  
Author(s):  
Jeremy P. Braybrooke ◽  
Andrew Slade ◽  
Gael Deplanque ◽  
Richard Harrop ◽  
Srinivasan Madhusudan ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document